Johnson & Johnson $JNJ is New England Asset Management Inc.'s 10th Largest Position

Key Points

• New England Asset Management Inc. increased its stake in Johnson & Johnson by 13.0%, owning a total of 63,464 shares valued at approximately $10.5 million, making it the firm's 10th largest investment.
• Johnson & Johnson reported earnings per share of $2.77 for the last quarter, beating expectations and achieving a revenue of $23.74 billion, up 5.8% year-on-year.
• The company declared a quarterly dividend of $1.30 per share, which will be paid on September 9, reflecting an annualized yield of 2.9% and a payout ratio of 55.61%.

New England Asset Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,464 shares of the company's stock after purchasing an additional 7,325 shares during the period. Johnson & Johnson accounts for 1.7% of New England Asset Management Inc.'s holdings, making the stock its 10th biggest holding. New England Asset Management Inc.'s holdings in Johnson & Johnson were worth $10,525,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NFJ Investment Group LLC boosted its stake in Johnson & Johnson by 30.9% in the first quarter. NFJ Investment Group LLC now owns 97,511 shares of the company's stock valued at $16,171,000 after acquiring an additional 23,012 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its stake in shares of Johnson & Johnson by 0.9% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 309,530 shares of the company's stock valued at $51,332,000 after buying an additional 2,810 shares in the last quarter. NewEdge Advisors LLC lifted its stake in Johnson & Johnson by 13.0% in the 1st quarter. NewEdge Advisors LLC now owns 333,821 shares of the company's stock worth $55,361,000 after purchasing an additional 38,425 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Johnson & Johnson by 17.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 379,870 shares of the company's stock worth $62,987,000 after purchasing an additional 56,040 shares in the last quarter. Finally, Investmark Advisory Group LLC increased its holdings in shares of Johnson & Johnson by 0.8% in the 1st quarter. Investmark Advisory Group LLC now owns 20,633 shares of the company's stock worth $3,422,000 after buying an additional 159 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $0.57 during trading hours on Friday, reaching $178.20. The company had a trading volume of 9,733,095 shares, compared to its average volume of 7,556,979. The business has a fifty day moving average price of $168.57 and a 200-day moving average price of $160.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $429.15 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Analyst Ratings Changes

A number of brokerages have recently commented on JNJ. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Friday. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Finally, Guggenheim reissued a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.